Are CSF Biomarkers Useful as Prognostic Indicators in Diagnostically Unresolved Cognitively Impaired Patients in a Normal Clinical Setting


&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Despite an extensive evaluation program, patients may remain diagnostically unresolved with regard to the etiology of their cognitive dysfunction. Cerebrospinal fluid neuroinflammation and Alzheimer disease (AD) biomarkers may act as indicators of neurodegenerative disorders in diagnostically unresolved patients. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; Data on 348 patients were retrospectively evaluated. All participants had a standardized diagnostic workup and follow-up in a memory clinic. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Aβ&lt;sub&gt;42&lt;/sub&gt; levels and Aβ&lt;sub&gt;42&lt;/sub&gt;/p-tau ratios were reduced and levels of t-tau and p-tau as well as the t-tau × p-tau/Aβ&lt;sub&gt;42&lt;/sub&gt; ratio were elevated in diagnostically unresolved patients who clinically progressed, compared to a stable group. No differences in neuroinflammatory parameters were found. &lt;b&gt;&lt;i&gt;Conclusion:&lt;/i&gt;&lt;/b&gt; AD biomarkers - in particular the Aβ&lt;sub&gt;42&lt;/sub&gt;/p-tau ratio, but not neuroinflammatory parameters - predicted clinical progression, regardless of etiology.</jats:p

Similar works

Full text



Last time updated on 25/02/2019

This paper was published in Crossref.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.